Edwards Lifesciences Corporation $EW Holdings Decreased by Corebridge Financial Inc.

Key Points

• Corebridge Financial Inc. reduced its stake in Edwards Lifesciences Corporation by 3.4%, owning 147,118 shares worth $10.66 million after selling 5,198 shares in the first quarter.
• Multiple institutional investors increased their positions in Edwards Lifesciences, with AQR Capital Management lifting its stake by a significant 43.5%.
• Analysts have generally positive views on Edwards Lifesciences, with three firms rating it as a "Strong Buy" and a consensus price target of $85.90.

Corebridge Financial Inc. lessened its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 3.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 147,118 shares of the medical research company's stock after selling 5,198 shares during the period. Corebridge Financial Inc.'s holdings in Edwards Lifesciences were worth $10,663,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in EW. Jennison Associates LLC increased its holdings in Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after buying an additional 2,576,383 shares during the last quarter. Brown Advisory Inc. raised its stake in shares of Edwards Lifesciences by 7.6% in the fourth quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company's stock valued at $603,741,000 after acquiring an additional 575,699 shares during the period. Deutsche Bank AG increased its stake in Edwards Lifesciences by 10.4% in the 4th quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company's stock worth $511,044,000 after buying an additional 652,923 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Edwards Lifesciences by 8.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock worth $482,621,000 after buying an additional 513,468 shares during the period. Finally, Northern Trust Corp increased its position in Edwards Lifesciences by 21.8% during the 4th quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after purchasing an additional 1,165,845 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,014 shares of company stock worth $1,698,844. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Up 0.3%

Shares of Edwards Lifesciences stock traded up $0.25 during trading hours on Monday, reaching $81.48. 2,743,784 shares of the company's stock were exchanged, compared to its average volume of 3,802,425. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00. The firm has a market capitalization of $47.84 billion, a price-to-earnings ratio of 11.72, a price-to-earnings-growth ratio of 3.92 and a beta of 1.07. The company has a fifty day moving average of $78.31 and a 200-day moving average of $75.01. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on EW shares. Robert W. Baird lifted their target price on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Barclays upped their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Wall Street Zen upgraded shares of Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Finally, Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.